Syntara Limited has released a press release.
FDA Gives Green Light to Start Myelofibrosis Phase 2 Study
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Syntara
- US$7 million Bronchitol Launch Milestone Brought Forward
- Fourth Quarter Activity Report
- Pharmaxis Quarterly Shareholder Update - March 2020
- PXS Cancer Drug Ready to Commence Phase 2 Studies Q4 2020
- Quarterly Shareholder Update - December 2019
Later from Syntara
- Pharmaxis Awarded $1M Australian Government Grant
- Boehringer Ingelheim discontinues development of BI 1467335
- September Quarter 2020 Activity Report
- Pharmaxis Prioritises Clinical Program on Myelofibrosis
- Pharmaxis Receives US$7m milestone from Chiesi
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara